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Accumulation of 06-Methylguanine in
Human DNA after Therapeutic Exposure
to Methylating Agents and Its Relation-
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Christos Valavanis,' Viki A. Boussiotis,2 and
Gerasimos A. Pangalis2
O-Methylguanine hasbeenmeasuredinperipheral bloodleukocytesof14patientsduringone or morecyclesoftreat-
mentwith procarbazine (dailytreatmentfor 10days)andin 12patientsduringone or more cydesoftreatmentwithdacar-
bazine (single dose percycle). Adduct fornation atlevels uptoabout 04fmole/AgDNA wasdetected in all procarbazine-
andall but onedacarbazine-treated patients at somepointaftertreatment. O-Methylguanine accumulated during pro-
carbazine treatment in adose-related manner (mean rateofaccumulation2.8 x 10-4fmole4pgDNA permg/ni2 dose) and
appeared to approach a plateau by the end of the cycle (above 600 mg/m2 cumulative dose). The average rate of
O-methylguanine formation 2 hr after dacarbazine treatment was 11 ± 8 x 10-4 fmole/pg DNA per mg/m2 dose. In-
dividuals examined on morethan one treatment cycle witheither drugshowed broadly similarmethylation responses.
The rateofadductaccumulation showed anonsignificant, negativecorrelationwiththe pretreatmentlymphocytelevels
ofthe repair enzyme O-alkylguanine-DNA alkyltransferase (AGI) inthe caseofprocarbazine and nocorrelation in the
case ofdacarbazine. No consistent lymphocyte AGT depletion was noted as a result oftreatment with either drug.
Nocorrelation between O'-methylguanineformationandhematologicaltoxKicity wasobserved. Ineightpatientsshowing
full remission after treatment withdacarbazine, the valueofO-methylguanine (averaged overallthecycles) was0.252
± 0.120fmole/pg DNAwhile infourpatientsshowingpartial or no responseitwas0.087 ± 0.110fmole/ugDNA (p < 0.05).
Oneofthetwononrespondingprocarbazine-treated patientsshowed verylowlevelsofO-methylguanine during acycle
ofobservation ofDNA adduct formation.
Human bloodleukocytes areabout 5-fold less susceptible than those ofthe rat to accumulation ofO-methylguanine
during exposure toprocarbazine. Furthermore, similaradductlevels werefoundinratperipheral bloodleukocytesand
lymphocytes, bone marrow, andlymphnodes, suggestingthatlevelsobservedinhumanbloodleukocytes mayreflectthose
inthepresumedtargettissuesfortheleukemogenic (bonemarrow) andthetherapeutic (lymphnodes)effectsofprocar-
bazine. Thepossible useoftheseobservations intheassessment ofcarcinogenic riskstohumansexposedtoprocarbazine
or environmental methylating agents such as dimethylnitrosamine is discussed.
Introduction
The measurement ofDNA adducts formed inpatients treated
withalkylating drugs isofinterestbecause suchadducts may in-
dicate thebiological dose received atthe level ofthe individual
patient, which may be correlated with therapeutic response or
long-term complications (mainly therapy-induced carcino-
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genesis). Duringthepast2years wehave focusedourattention
on two methylating agents used in the chemotherapy of
Hodgkin's lymphoma, procarbazine (PCZ) [N-isopropyl-a-(2-
methylhydrazino)-p-toluamide] and dacarbazine (DCZ)
[5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide] (1,2).
Both drugs are converted by metabolism to SN1-type
methylating intermediates and give rise to a rangeofDNA ad-
ducts, including 06-methylguanine (06-MeG) (3,4), anadduct
believed to play an important role in carcinogenesis, muta-
genesis, and cytotoxicity (5-7). One ofthe most widely used
therapeutic protocols forHodgkin's lymphoma, theMOPPpro-
tocol (using PCZ in combination with nitrogen mustard, vin-
cristine, andprednisone), hasbeen showntobeassociatedwith
anincreasedriskofacutenonlymphocytic leukemiaintreated in-
dividuals, giving rise to a cumulative risk of more than 10%KYRTOPOULOSETAL.
within 10 yearsoftreatment(8-10). Analternativeprotocol, the
ABVDprotocol (usingdacarbazine incombination withadria-
mycin, bleomycin, and vincristine), although not so far shown
tobeleukemogenic, may notbecompletely freeofcarcinogenic
risk (11).
Apart fromconsiderations oftherapy-induced carcinogenesis,
anadditional reason that makes the study ofthemethylation of
humanDNAby PCZandDCZofinterestistheneed todevelop
methodologies for assessing ofthe risks posed to the general
population by exposure to environmental methylating agents.
Such exposure is known to occur widely via contact with ex-
ogenous or endogenously formed chemicals (12-15).
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Here wereviewthe current statusofourongoing studies and
discuss theobserved relationships between exposure dose, ad-
duct formation, DNA repairandbiological effects and discuss
theirusefulness inthe assessmentofcancerriskassociated with
exposure to PCZ and DCZ and to environmental methylating
agents.
Materials and Methods
Procarbazine treatment of patients involved 50-mg doses,
three times per day (about 80 mg/m2day) for 10 consecutive
days, followed by a 3-week rest period, a treatment normally
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FIGURE 1. Accumulation of06-methylguanine in blood leukocytes of 14 individuals during one or morecyclesoftreatment with procarbazine. (Open symbols)
Individuals with full remission attheend ofthecycle; (filledsymbols) individuals with partial or no remission. The responseofeach individual afterthe par-
ticular cycledescribed andaftertheend ofthe full course oftreatment is indicated as follows: (++) full remission; (+) partial remission; (-) recurrence. No
overall clinical assessment is available for some patients who had not yetcompleted therapy at the time ofwriting.
0.30.
lndhv. no.
0. 25- -0-0
5 +/++
6++/++
o-*-O 7++/++
V.20
ED.15A
20.10 .. / T10
0-
00.05 ... /.".
0.00 !Wm mm ..., - . - . - .
u.av
indiv. no./cycle no.
i02.5 *r*- 11/1 + C
0i * 11/2 +
0.1 1.20
1<~ ~ ~
a
10to°
0.00 _~tw unu~wrwwtvuw u
indiv. no./cycle no.
*E* 12/1 + E
*-* 12/2 +
U.a ... .........................................
indiv. no./cycle no.
,0.25 * * 13/1 +/±+ F
i v v 13/2 +/++
E 0 0-0 1 3'3 9- oO.20S ..
E0.15
1010-
E0
0005
0.004. iu vrwwwwut wut wu n-ut viw wu n-ut~~~~~~~~~~~~~~~~~~~~~~~~~~~
14406-METHYLGUANINEDOSIME7RYAFTERPROCARBAZINE ORDACARBAZINE
repeated forsix cycles. Other drugs employed inthe same pro-
tocol included vincristine and cyclophosphamide or me-
chlorethamine hydrochloride. EachcycleofDCZtreatment in-
volved a single injectionofthedrug (300mg, about 160 mg/M2)
followed2 hrlaterby IV injectionsofbleomycin, vinblastin, and
epirubicin. Thistreatmentwas repeatedevery 15daysforatotal
offour to six cycles. Blood samples were collected from each
PCZ-treated patientjust before the start of a cycle and on in-
dicateddaysduring thecycle, 4hrafterthemorning intakeofa
50-mg PCZtablet. ForDCZpatients, blood samples werecol-
lectedjustbefore and 1 hrafter DCZadministration as well as
onthenext 1-2days (wherepossible). Insomecasesaduplicate
portion of blood was collected and immediately used for the
isolationoflymphocytesandmeasurementof06-alkylguanine-
DNA alkyltransferase (AGT). Details of the assays used for
determining 06-MeG and AGT havebeen published (1,2,16).
Procarbazine-treatment offemale Sprague-Dawley rats (150
g) was carried outby daily gavage (10mg/kg, 59 mg/M2) for 10
days. Groupsoffouranimalswerekilled24hraftertheyreceived
the indicated cumulative doses. In a separate series of ex-
periments, rats were given single IP doses of PCZ or di-
methylnitrosamine (DMN) atthedosesindicatedandkilledafter
2 or 6 hr, respectively.
Results and Discussion
Fourteenpatients (twelve withHodgkin's lymphomaandtwo
with non-Hodgkin's lymphoma) on PCZ treatment and twelve
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FIGURE 2. 06-methylguanine in blood leukocytes of 14 individuals 1-49 hr
aftertreatment withdacarbazineforone or morecycles. (Opensymbols) In-
dividuals with full remission attheendofacycle; (filledsyfbols) individuals
with partial or no remission.
Hodgkin's lymphomapatientsonDCZtreatmentwerefollowed
for up to four cycles ofchemotherapy. In almost all cases, no
06-MeGcouldbedetectedpriortothestartofatreatmentcycle,
even in patients starting a second or subsequent cycle, but
06-MeGwasdetectedatsomepointaftertreatment(Figs. 1 and
2). Adducts accumulated during PCZ treatment, usually
reaching about 0.2-0.3 fmole/yg DNA (0.32-0.48 ,mole
06-MeG/moleguanine) attheendofeachcycle. Slightlyhigher
adduct levels were seen2 hrafter treatment with DCZ. Where
the same individuals were followed for more thanone cycle of
treatment, broadlysimilarmethylationresponseswereobserved.
Inallcaseswheredatawereavailableforthe24hrimmediately
after cessation of treatment, a decrease in adduct levels was
observed amounting to 44 8% (n = 3) for PCZ-treated in-
dividuals and 43 ± 19% (n = 7) forDCZ-treated individuals.
AsindicatedinFigure3, theaccumulationof06-MeGinPCZ-
treated individuals as a group is linearly related to cumulative
dose (with a slope of 2.8 x 10 4 fmole/jLg DNA per mg/M2
dose)andapproaches aplateauaboveacumulativedoseof600
mg/i2. InDCZ-treatedindividuals,theaveragelevelof06-MeG
found2hrafterexposurewas0.20 ± 0.14fmole/pgDNA, cor-
responding to a rate offormation of 11 ± 8 x i0 4 fmole/Ag
DNA per mg/m2 dose.
As already reported, no consistent changes in lymphocyte
AGT levels were observed during PCZ treatment (1) and the
averagevalueofAGTremainedconstantthroughoutthecycle. A
similar picture was obtained with patients on DCZ treatment,
where a) no significant differences were seen between AGT
valuesbeforeandaftertreatmentandb)AGTlevelsinthesame
patientspriortothestartofrepeatedcyclesweresometimescon-
stantandsometimeschangedineitherdirection (2). Theoverall
picturethatemergesfromourstudies isthatnosignificant AGT
depletionoccurred in mostcases as aresultofsuiciderepairof
06-MeGadductsformedinthecontextofthechemotherapypro-
tocols weexamined. Thiscanbeexplainedby thelargeexcessof
lymphocyteAGTpresentin mostindividuals examined (usual-
ly5-15fmole4cgDNA)relativetotheobservedadductlevelsand
by the de novo synthesis ofAGT (17). Significantdepletion in
lymphocyte AGT was recently reported by Lee et al. (17) in
melanoma patients treated with high doses ofDCZ (up to 800
mg/m2), about5-foldhigherthanthedosesusedinourprotocols.
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FIGURE 3. 06-methylguanine accumulation in blood leukocyte DNA as a
functionofthecumulativedoseofprocarbazine. Eachpoint represents the
meanof3-14 individualssampled for upto3consecutivecycles. Barindicate
SDs.
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Examinationof06-MeGaccumulation indifferent individuals
has provided evidence that interindividual variability ofAGT
levels may be an important parameter influencing adduct ac-
cumulation during exposure toPCZ (1). Basedonthecurrent-
ly available data, while an inverse trend between lymphocyte
AGT and 06-MeG accumulation is consistently observed, this
correlationdoes notreachstatistical significance (Fig. 4). Inthe
caseofDCZexposure, formationof06-MeGdoesnotshowany
correlation withlymphocyte AGTbeforeexposure. Itispossible
thatanyunderlying relationship betweenadductformationand
AGTrepairactivity is inthiscaseconfounded bydifferences in
individual rates ofDCZ metabolism.
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Relationships between O-MeG Accumulation
andthe Clinical Effects ofPCZ and DCZ
Dacarbazine. Nocorrelationbetween 06-MeGlevelsandthe
change in white blood cell (WBC) count was observed. Figure
5 shows the levels of06-MeG inDCZ-treated patients classified
according toclinical response. The meanvalueof (6-MeGafter
eachcycle inindividuals showing full remissionofclinical symp-
toms attheendofthe samecycle(0.236 ± 0.146finole/4g DNA)
is higher than that in partial or nonresponders (0.156 ± 0.132
fmole/,ug DNA), although the difference is not statistically
significant (p = 0.18). Ifclassification isbased onoverall clinical
responseandthe 06-MeGlevels areaveraged overallthe treat-
ment cycles for each individual, the corresponding values
become 0.252 + 0.104 fmole/4Ag DNA and 0.087 ± 0.110
fmole/,ug DNA, respectively (p < 0.05). While possibly in-
dicativeofacorrelation, thesecomparisons areclearly limited
by thesmall numberofindividuals forwhichfullclinical data are
currently available. Nomeaningful comparisons ofAGT levels
inthedifferent groups canbemadebasedonthecurrently limited
available data.
Procarbazine. As already mentioned, 12 ofthePCZ-treated
patients hadHodgkin'slymphomaand2 (nos. 1 and2) had non-
Hodgkin's lymphoma. Ofthepatientswhohave sofarcompleted
the full course of PCZ treatment, all have shown good thera-
o -s u.usu
0 _
E ¢:
-6 0.025
0 0
c 0v
C C
- 0.015
E GL
<
uG 0.010
1 0.005- _D E
o % f%%
0.0
.*
0
.
*
0.1 0.2 0.3 0.4 0.5
AGTo (fmol//zg protein)
FIGURE 4. The rateofaccwnulationof06-methylguanine (06-MeG) during
treatment withprocabarzine indifferent individuals as afunctionofpretreat-
ment lymphocyte 06-alkylguanine-DNA alkyltransferase (AMg) values. The
rateof06-MeGaccumulation wascalculated astheleast-squares slopeofthe
corresponding 06-MeG versus cumulative procarbazine dose curve inFigure
I A-G. Samples collectedafterday 10 wereexcluded, as were samples col-
lectedafterday 7 from individual no. 2(forwhomextensivelossofmethyla-
tion was observed afterday 7).
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FIGURE 5. Scattergram of 06-methylguanine levels 2 hr after dacarbazine
treatmentrelative toclinical response attheendofaparticularcycle(upper
panel) orofthe full courseoftreatment(lowerpanel). Inthelowerpanel, the
06-methylguaninevaluesindicated aretheaveragesofthevaluesaftereach
cycle forwhichthey havebeenmeasured. Thedottedlines indicatethe means
ofthe full responderandpartial responder/nonresponder groups.
peutic response(fulldiseaseremission) withtheexceptionoftwo
patients (no. 2, anon-Hodgkin's lymphomapatientand no. 4, a
Hodgkin's lymphoma patient). This similarity in therapeutic
responses, in combination with the similarity of methylation
responses (Figs. IA-G), makesthe assessmentofany relation-
shipbetweenthetwoparametersdifficult. However, itis notable
that the two individuals in whom therapy failed were the only
ones exhibiting an abnormal methylation pattern: patient no. 2
accumulatedhighlevelsofadducts uptoday 7 andsubsequent-
ly showed anunexplainedrapidlossofadducts, andpatient no.
4accumulated very low adductlevelsthroughoutthe treatment
cycle.
Animal-to-HumanExtrapolations forPCZ,
DCZ, andEnvironmental Methylating Agents
A question offundamental importance in any attempt to use
blood leukocyte adduct levels as indicators of tissue-specific
therapeutic effectiveness orcarcinogenicriskistheirrelationship
toadductlevelsinthetargetcells. Fongetal. (18)haveshownthat
dosesofPCZandmethylnitrosourea resulting insimilarextents
of mammary carcinogenesis in female rats yield different
amountsof06-MeGintotal mammaryDNA, implyingthatthe
cell-specific distribution ofadducts may be important in PCZ
carcinogenesis. In order to obtain an indication of the tissue
distributionof06-MeGformedbyPCZ, rats weretreateddaily
peroswith PCZfor 10dayswith adosecomparable tothatused
in the MOPP protocol. Accumulation of similar amounts of
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FIGURE 6. Accumulation ofC6-methylguanine inrat DNAduringtreatment
with dacarbazine (10 mg/kg) for 10 days. (V) Times ofprocarbazine ad-
ministration. FordetailsofthetreatmentscheduleseeMaterialsandMethods.
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FIGURE 7. Comparative formationof06-methylguanine inrat(filledsymbols)
and human (open symbols) blood leukocytes afterrepeated treatment with
procarbazine (circles) anddimethylnitrosamine (squares). Thedotted line
refers tothemethylationofhumanleukocyte DNAbydimethylnitrosamine
and isextrapolated fromthatofthe ratby assuming similarrelativespecies
sensitivities asobserved forprocarbazine methylation. Thehorizontal dashed
line indicates the possible range of human daily exposure to dimethyl-
nitrosamine.
06-MeG intheliverandlungandabout2.5-foldlowerlevelsin
bloodleukocytes, bonemarrowandleucocytesoccurred(Fig. 6),
suggesting thatadduct levels inhumanbloodleukocytes maybe
a good indicator oflevels in the bonemarrow (target tissue for
leukemogenesis) and the lymph nodes (target tissue for
chemotherapy). Furthermore, comparison of the rates of ac-
cumulationof06-MeG inratandhumanbloodleukocytes sug-
gests that humans have 5-fold lower susceptibility than rats to
leukocyte 06-MeG induction by PCZ.
Figure7describesafirstapproachtowardusingtheabovedata
toextrapolatetheexpectedextentof06-MeGformationinhuman
blood leukocytes after exposure to DMN. Based on the com-
parisonof06-MeG formationin ratandhumanbloodleukocytes
by PCZandassuming similarrelativespeciessusceptibilities to
DMN-induced methylation, current daily human exposure to
DMN (0.1-10 tsg) (12,19) would be expected to give rise to
06-MeG levels well below 1 x 10 9mole/mole guanine.
This manuscript was presented at the Conference on Biomonitoring and
Susceptibility Markers inHumanCancer: Applications inMolecularEpidem-
iology and RiskAssessmentthatwasheldinKailua-Kona, Hawaii, 26October-I
November 1991.
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